Genmab — November 2016
-
sc dara klar: SC DARA-PH20 was well tolerated and achieved serum trough concentrations similar to or greater than IV DARA with a lower rate of IRRs compared to IV DARA over a significantly shorter infusion time. Preliminary data suggest that in this pt population SC DARA-PH20 may enable similar response rates to IV DARA monotherapy. The 1800 mg dose level of DARA-PH20 was selected as the RP2D for part 2 of the study. These early data support further study of SC DARA in clinical trials.
-
mon ikke snart shorterne fra usa er stået op. de må gerne være med på et tilbagekøb
-
-
-
Kl 16. investor1989.
-
To timer på motorvejen har gjort godt ved kursen.
-
Jeg skal lige have fundet en hyggelig rasteplads til vores Q&A.
-
Er der nogen, der har link til Q&A sessionen?
-
Meld jer til Q&A her.
-
-
Når I er tilmeldt kan I følge med i Q&A chatten. Der kommer et transcript senere.
-
Noget spændende i abstracts?
nu mangler vi bare de rigtig ... 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind